OTC Medicines

CHPA strongly supports the OTC Monograph System, but we believe that policy reforms could make the system more flexible, responsive, and accommodating to innovation.

Substance Abuse Treatment, Prevention, and Policy recently published a case study authored by CHPA about the association’s efforts to curb teen abuse of OTC cough medicine containing dextromethorphan.

CHPA released the following statement today in support of a Delaware law prohibiting the sale of OTC medicines containing the cough suppressant dextromethorphan (DXM) to minors.

Unlike other drugs subject to user fees, nonprescription drugs under the Monograph system are not subject to FDA approval prior to marketing. Many of these ingredients have been marketed for more than 40 years, with a long history of safe use. We must define value differently than industries subject to FDA approval prior to marketing.

CHPA is pleased to lend its strong support for the DXM Abuse Prevention Act (S. 2994), introduced into the U.S. Senate by Senators Bob Casey Jr. (D-PA) and Lisa Murkowski (R-AK).

CHPA issued the following statement following the Food and Drug Administration’s announcement of a public meeting to gather stakeholder input on the potential development of a user fee program for nonprescription monograph drugs.

CHPA applauds the state of Georgia for becoming the thirty-third state to adopt the real-time, stop-sale technology called the National Precursor Log Exchange (NPLEx).

CHPA, which represents leading manufacturers of OTC cough medicines, strongly supports this legislation and is joined many by substance abuse prevention organizations such as the Community Anti-Drug Coalitions of America and the Partnership for Drug-Free Kids.